A phase 1b trial evaluating SY-5609 in combination with a Bruton's tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma
Latest Information Update: 17 Jan 2022
At a glance
- Drugs SY 5609 (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 10 Jan 2022 According to a Syros Pharmaceuticals media release, this trial is expected to begin in the second half of 2022, with data expected mid-2023
- 23 Sep 2021 New trial record
- 20 Sep 2021 According to a Syros Pharmaceuticals media release, this trial is expected to begin in the first half of 2022.